Clinical Trial Update: A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. [Phase 1]

View source ↗

Summary

Phase 1 TAS-102 (trifluridine/tipiracil) has completed a study in patients with advanced gastrointestinal tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancers

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced Gastrointestinal Tumors | Phase 1 | Status: COMPLETED